News

Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The decision was based on events of suicidal ideation

Repatha is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol

Aptensio XR is an extended-release formulation of methylphenidate capsule with an onset of effect of one hour and 12-hour duration of effect with about 40% of the active

A total of 2,157 patients with AHF were enrolled in the trial from over 200 centers across the US, Europe, Canada and Latin America. The TRUE-AHF Phase III

Omidria helps to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction) as well as to reduce postoperative eye pain. The company’s PharmacoSurgery product Omidria, which contains the mydriatic

The company is seeking approval for adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies

The European Commission, which has the authority to approve medicines for the European Union (EU), will now review the CHMP positive opinion. Bristol-Myers Squibb senior vice-president and head

The positive opinion of Keytruda was based on efficacy and safety data in more than 1,500 patients with advanced melanoma in three studies, a large Phase Ib KEYNOTE-001

Mepolizumab is delivered in a 100mg fixed dose via a subcutaneous injection every four weeks. The NDA for mepolizumab is for adults and adolescents aged 12 years or